The cancer drug paclitaxel just got more effective. For the first time, researchers from the University of North Carolina at Chapel Hill have packaged it in containers derived from a patient’s own immune system, protecting the drug from being destroyed by the body’s own defenses and bringing the entire payload to the tumor.
“That means we can use 50 times less of the drug and still get the same results,” said Elena Batrakova, Ph.D., an associate professor in the UNC Eshelman School of Pharmacy.
Ref: Development of exosome-encapsulated paclitaxel to overcome MDR in cancer cells. Nanomedicine: Nanotechnology, Biology and Medicine (13 November 2015) | DOI: 10.1016/j.nano.2015.10.012